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Abstract
Background: The occurrence of aberrant functional connectivity in the neuronal circuit is one of
the integrative theories of the etiology of schizophrenia. Previous studies have reported that the
protein and mRNA levels of the synapsin 2 (SYN2) and complexin 2 (CPLX2) genes were decreased
in patients with schizophrenia. Synapsin 2 and complexin 2 are involved in synaptogenesis and the
modulation of neurotransmitter release. This report presents a study of the association of
polymorphisms of SYN2 and CPLX2 with schizophrenia in the Korean population.
Methods: Six single nucleotide polymorphisms (SNPs) and one 5-bp insertion/deletion in SYN2
and five SNPs in CPLX2 were genotyped in 154 Korean patients with schizophrenia and 133 control
patients using direct sequencing or restriction fragment length polymorphism analysis. An
intermarker linkage disequilibrium map was constructed for each gene.
Results: Although there was no significant difference in the genotypic distributions and allelic
frequencies of either SYN2 or CPLX2 polymorphisms between the schizophrenia and control
groups, the two-way haplotype analyses revealed significant associations with the disease (P < 0.05
after Bonferroni correction). The three-way haplotype analyses also revealed a significant
association of SYN2 with schizophrenia (P < 0.001 after Bonferroni correction).
Conclusion:  These results suggest that both SYN2  and  CPLX2  may confer susceptibility to
schizophrenia in the Korean population.
Background
Schizophrenia is a severe, chronic mental illness affecting
0.5–1.5% of the general population worldwide [1]. The
contribution of genetic factors to the vulnerability to
schizophrenia has been well established by family, twin,
and adoption studies that have suggested a significant
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heritability of approximately 50–70% [2]. Many studies
have attempted to identify the allelic variants that confer
susceptibility to the illness, but no single genes have been
identified that produce a major effect on the vulnerability
[3].
Recently the synaptic hypothesis of schizophrenia has
gained attention by attributing the fundamental pathol-
ogy of schizophrenia to the dysfunction of synaptic trans-
mission involving various molecules [4]. Synapsins, a
family of synaptic vesicle-associated phosphoproteins,
play a crucial role in the regulation of neurotransmission,
synaptogenesis, and neuronal plasticity [5]. Three human
synapsin genes have been identified (SYN1,  2, and 3;
OMIM 313440, 600755, and 602705) [6]. Complexin 1
and complexin 2, which are encoded by CPLX1 (OMIM
605032) and CPLX2 (OMIM 605033), respectively, and
are also called synaphins, are pre-synaptic membrane pro-
teins that preferentially bind to syntaxin within the
SNARE (soluble N-ethylmaleimide-sensitive fusion
attachment protein receptors) complex. These proteins
are important regulators of transmitter release immedi-
ately preceding vesicle fusion [7]. Previous studies have
demonstrated that the concentrations of synapsins and
complexins are reduced in the brains of schizophrenics
[8,9]. The expression levels of both synapsins were signif-
icantly decreased in the hippocampal tissue of schizo-
phrenic patients [10]. The levels of synapsin 2 and
complexin 2 mRNA were also significantly reduced in the
prefrontal cortex, cerebellum, and hippocampus of schiz-
ophrenics [11-14].
SYN2 was mapped to chromosome 3p25 [15], and CPLX2
is located on chromosome 5q35.3 (OMIM 605033).
These loci were identified as potential regions conferring
susceptibility to schizophrenia in diverse populations
[16-18]. Based on their localization, well-established neu-
robiological roles, and expression patterns in schizo-
phrenic patients, we selected SYN2  and  CPLX2  as
candidate genes for conferring susceptibility to schizo-
phrenia. In this report, we present an association study of
SYN2 and CPLX2 with schizophrenia using 12 polymor-
phisms in the Korean population.
Results
SYN2 polymorphisms in the schizophrenia and control 
groups
Of the seven polymorphisms in SYN2, rs2623873 (SYN2-
1) is located in the promoter region, whereas the others
are all located in the intronic regions (SYN2-2–7) (Fig. 1,
Genomic organization of SYN2 and CPLX2 and locations of SNPs Figure 1
Genomic organization of SYN2 and CPLX2 and locations of SNPs. a; SYN2 spans over 140 kb and is composed of 14 
exons. Seven markers are indicated with the dbSNP reference ID http://www.ncbi.nlm.nih.gov/SNP. b; CPLX2 spans over 83 kb 
and is composed 3 exons. Five markers are indicated with the dbSNP reference ID http://www.ncbi.nlm.nih.gov/SNP.Behavioral and Brain Functions 2005, 1:15 http://www.behavioralandbrainfunctions.com/content/1/1/15
Page 3 of 7
(page number not for citation purposes)
Table 1). The genotypic distributions and allelic frequen-
cies of polymorphisms in SYN2 were determined in 113
schizophrenic patients and 114 normal healthy controls
by direct sequencing or DdeI RFLP. The genotypic distri-
butions and allelic frequencies of polymorphisms in
SYN2 are shown in Table 2. The average allelic frequency
of the SNPs was 0.312. Given the equivalent frequency for
the susceptible allele, the expected detection power for
SYN2  was 0.9538 to 0.9929 under the multiplicative
model with a genotype relative risk = 1.8 to 2.0 [22]. None
of the SNPs showed any significant deviation from Hardy-
Weinberg equilibrium (P > 0.05). We observed no signif-
icant difference in the genotypic distributions and allelic
frequencies between the schizophrenics and control
groups (Table 2).
We compared the LD for all possible two-way compari-
sons of the SNPs in the controls (Table 3). The pairwise D'
values for the seven SNPs were consistently high, except in
one instance (SYN2-2 vs. SYN2-6; D' = 0.300, r2 = 0.200).
Out of the 21 possible pairs of SNPs, significant haplotype
associations with schizophrenia were observed for 4 pairs:
SYN2-1 – SYN2-2 (χ2 = 27.58, df = 3, P = 4.45 × 10-6),
SYN2-2 – SYN2-4 (χ2 = 16.46, df = 3, P = 9.12 × 10-4),
SYN2-2 – SYN2-7 (χ2 = 8.08, df = 3, P = 0.044), and SYN2-
3 – SYN2-4 (χ2 = 10.66, df = 3, P = 0.014) (Table 3). Even
after the Bonferroni correction (number of haplotypes, n
= 21), the associations of the SYN2-1 – SYN2-2 and SYN2-
2 – SYN2-4 haplotypes with schizophrenia remained sig-
nificant (Pcorr = 9.35 × 10-5 and Pcorr = 0.019) (Table 3). The
T allele-the deletion allele haplotype for the SYN2-1 –
SYN2-2 combination and the deletion allele-the G allele
haplotype for the SYN2-2 – SYN2-4 combination were
observed more frequently in schizophrenia than the con-
trols (Table 4).
We also investigated the association of three-way haplo-
types formed by SYN2-1, SYN2-2, and SYN2-4 with schiz-
ophrenia. A significant difference in the haplotype
frequencies between the schizophrenia and control
groups was observed (χ2 = 35.0, df = 7, Pcorr = 1.1 × 10-5).
For the combination of SYN2-1, SYN2-2, and SYN2-4, the
estimated frequencies of the T-deletion-G haplotype dif-
fered between the schizophrenia (0.570) and controls
groups (0.440).
CPLX2 polymorphisms in schizophrenia and control 
groups
Of the five SNPs in CPLX2, rs2247916 (CPLX2-1) is
located in the promoter region, rs2243404 (CPLX2-2) is
located in the 5'UTR, and the others are located in the
intronic regions (Fig. 1, Table 1). We determined the gen-
otypic distributions and allelic frequencies of the SNPs in
154 schizophrenic patients and 133 normal healthy con-
trols by direct sequencing or RFLP analysis. The genotypic
distributions and allelic frequencies for CPLX2 SNPs are
shown in Table 2. The average allelic frequency of the
SNPs was 0.126. Given the equivalent frequency for the
susceptible allele, the expected detection power for CPLX2
was 0.7445 to 0.8802 based on the multiplicative model
with the genotype relative risk = 1.8 to 2.0 [22]. None of
the five SNPs showed any significant deviations from
Hardy-Weinberg equilibrium. We observed no significant
differences in genotypic distributions or allelic frequen-
cies between the schizophrenia and control groups (Table
2).
Table 1: Twelve polymorphisms genotyped in this study.
Gene Name dbSNP rs# Region Allele Methods
SYN2 SYN2-1 rs2623873 Promoter G/T Direct Sequencing
SYN2 SYN2-2 rs2308169 Intron ATGCT/- Direct Sequencing
SYN2 SYN2-3 rs308961 Intron T/G Direct Sequencing
SYN2 SYN2-4 rs308963 Intron C/G Direct Sequencing
SYN2 SYN2-5 rs308952 Introna A/G DdeI RFLP
SYN2 SYN2-6 rs2279750 Introna A/C Direct Sequencing
SYN2 SYN2-7 rs310762 Intron C/T Direct Sequencing
CPLX2 CPLX2-1 rs2247916 Promoter G/T MaeIII RFLP
CPLX2 CPLX2-2 rs2243404 5'UTR C/T Cac8I RFLP
CPLX2 CPLX2-3 rs890736 Intron C/T AvaII RFLP
CPLX2 CPLX2-4 rs890737 Intron C/T Direct Sequencing
CPLX2 CPLX2-5 rs4390706 Intron G/A Direct Sequencing
a Tissue inhibitor of metalloproteinase 4 (Timp4) gene is nested within the intron of SYN2 in reverse orientation.Behavioral and Brain Functions 2005, 1:15 http://www.behavioralandbrainfunctions.com/content/1/1/15
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Table 2: Genotype distributions and allele frequencies of each polymorphism of the SYN2 and CPLX2 in the schizophrenia and control 
groups.
Polymorphism Subjects Genotype distribution (frequency) Allele frequency
11 12 22 Pa 12Pb
SYN2-1 Cases (n = 113) 47 (0.416) 50 (0.442) 16 (0.142) 0.527 0.637 0.363 0.679
Controls (n = 114) 41 (0.360) 59 (0.518) 14 (0.122) 0.618 0.382
SYN2-2 Cases (n = 113) 40 (0.354) 55 (0.487) 18 (0.159) 0.758 0.597 0.403 0.438
Controls (n = 114) 36 (0.316) 56 (0.491) 22 (0.193) 0.561 0.439
SYN2-3 Cases (n = 113) 83 (0.735) 30 (0.265) 0 (0.000) 0.762 0.867 0.133 0.975
Controls (n = 114) 85 (0.746) 28 (0.246) 1 (0.009) 0.868 0.132
SYN2-4 Cases (n = 113) 49 (0.434) 45 (0.398) 19 (0.168) 0.722 0.633 0.367 0.612
Controls (n = 114) 44 (0.386) 51 (0.447) 19 (0.167) 0.610 0.390
SYN2-5 Cases (n = 113) 72 (0.637) 35 (0.310) 6 (0.053) 0.973 0.792 0.208 0.869
Controls (n = 114) 74 (0.649) 34 (0.298) 6 (0.053) 0.798 0.202
SYN2-6 Cases (n = 113) 67 (0.593) 39 (0.345) 7 (0.062) 0.786 0.765 0.235 0.622
Controls (n = 114) 63 (0.553) 44 (0.386) 7 (0.061) 0.746 0.254
SYN2-7 Cases (n = 113) 39 (0.345) 54 (0.478) 20 (0.177) 0.847 0.584 0.416 0.576
Controls (n = 114) 42 (0.368) 55 (0.482) 17 (0.149) 0.610 0.390
CPLX2-1 Cases (n = 154) 132 (0.857) 22 (0.143) 0 (0.000) 0.441 0.929 0.071 0.612
Controls (n = 133) 113 (0.850) 18 (0.135) 2 (0.015) 0.917 0.083
CPLX2-2 Cases (n = 154) 132 (0.857) 22 (0.143) 0 (0.000) 0.254 0.929 0.071 0.198
Controls (n = 133) 108 (0.812) 23 (0.173) 2 (0.015) 0.898 0.102
CPLX2-3 Cases (n = 154) 115 (0.747) 34 (0.221) 5 (0.032) 0.129 0.857 0.143 0.072
Controls (n = 133) 85 (0.639) 43 (0.323) 5 (0.038) 0.801 0.199
CPLX2-4 Cases (n = 154) 110 (0.714) 40 (0.260) 4 (0.026) 1.000 0.844 0.156 0.849
Controls (n = 133) 94 (0.707) 35 (0.263) 4 (0.030) 0.838 0.162
CPLX2-5 Cases (n = 154) 124 (0.805) 30 (0.195) 0 (0.000) 0.312 0.903 0.097 0.541
Controls (n = 133) 112 (0.842) 20 (0.150) 1 (0.008) 0.917 0.083
a Fisher's exact probability tests, case vs controls (2 × 3 genotype-based analysis)
b Fisher's exact probability tests, case vs controls (2 × 2 allele-based analysis)
Table 3: Pairwise linkage disequilibrium and haplotype association of SNPs in SYN2.
SYN2-1 SYN2-2 SYN2-3 SYN2-4 SYN2-5 SYN2-6 SYN2-7
SYN2-1 0.532 0.776 0.758 0.865 0.516 0.642
0.222 0.056 0.553 0.306 0.482 0.397
SYN2-2 4.45 × 10-6 a 0.613 0.453 0.734 0.300 0.429
0.044 0.250 0.174 0.200 0.225
SYN2-3 0.246 0.632 1.000 0.997 0.480 1.000
0.097 0.038 0.433 0.097
SYN2-4 0.845 9.12 × 10-4 a 0.014 1.000 0.480 0.806
0.395 0.433 0.650
SYN2-5 0.896 0.655 0.135 0.133 0.938 0.865
0.651 0.295
SYN2-6 0.116 0.892 0.602 0.602 0.147 0.722
0.278
SYN2-7 0.646 0.044 0.155 0.392 0.404 0.0.72
Upper diagonal top: D', bottom: r2 in controls; Lower diagonal: P value by χ2 test (df = 3)
a P < 0.05 after Bonferroni correctionBehavioral and Brain Functions 2005, 1:15 http://www.behavioralandbrainfunctions.com/content/1/1/15
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We compared LD for all possible two-way comparisons of
the SNPs in controls (Table 5). The pairwise D' values for
the five SNPs were consistently low, except in one instance
(CPLX2-2 vs. CPLX2-4; D' = 0.715, r2 = 0.011). Only one
pair of SNPs (CPLX2-1 vs. CPLX2-2) showed a significant
haplotype association with schizophrenia (χ2 = 16.28, df
Table 4: Estimated haplotype frequencies of the SYN2-1 – SYN2-2 and SYN2-2 – SYN2-4 combination on the SYN2
Haplotypes Estimated frequency
SYN2-1 SYN2-2 Cases Controls
T Deletion 0.583 0.461
T ATGCT 0.054 0.158
G Deletion 0.014 0.100
G ATGCT 0.349 0.281
SYN2-2 SYN2-4 Cases Controls
Deletion G 0.569 0.463
Deletion C 0.028 0.098
ATGCT G 0.064 0.146
ATGCT C 0.339 0.293
Table 5: Pairwise linkage disequilibrium and haplotype association of SNPs in CPLX2.
CPLX2-1 CPLX2-2 CPLX2-3 CPLX2-4 CPLX2-5
CPLX2-1 0.412 0.325 0.058 0.008
0.136 0.300 0.001 0.008
CPLX2-2 9.0 × 10-4 a 0.309 0.715 0.301
0.042 0.011 0.001
CPLX2-3 0.494 0.056 0.027 0.019
0.015 0.016
CPLX2-4 0.994 0.830 0.564 0.143
0.000
CPLX2-5 1.000 0.564 0.650 0.992
Upper diagonal top: D', bottom: r2 in controls; Lower diagonal: P value by χ2 test (df = 3)
a P < 0.01 after Bonferroni correction
Table 6: Estimated haplotype frequencies of the CPLX2-1 – CPLX2-2 combination on the CPLX2
Haplotypes Estimated frequency
CPLX2-1 CPLX2-2 Cases Controls
T C 0.010 0.036
T T 0.061 0.047
G C 0.919 0.862
G T 0.010 0.055Behavioral and Brain Functions 2005, 1:15 http://www.behavioralandbrainfunctions.com/content/1/1/15
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= 3, P = 0.0009), even after the Bonferroni correction (n =
10, Pcorr = 0.009, Table 5). For the combination of CPLX2-
1 – CPLX2-2, the G allele-the C allele haplotype was
observed more frequently in the schizophrenia group
than the control group (Table 6).
Discussion
In this study, we observed significant, pairwise haplotype
associations with schizophrenia for two pairs of SNPs in
SYN2 (SYN2-1 – SYN2-2 and SYN2-2 – SYN2-4; Pcorr =
9.35 × 10-5 and Pcorr = 0.019, respectively) and one pair of
SNPs in CPLX2 (CPLX2-1 – CPLX2-2, Pcorr = 0.009) (Table
3, 5). The three-way haplotype (SYN2-1, SYN2-2, and
SYN2-4) also showed a significant association with schiz-
ophrenia (Pcorr = 1.1 × 10-5). The SYN2-1 and CPLX2-1
SNPs are located in the respective promoter regions, -98
and -156. SYN2-1 was located within the GC box motif
and CPLX2-1 within the C/EBP motif in a database search
http://www.cbrc.jp/research/db/TFSEARCH. The positive
haplotype associations seem to be based on an increase of
LD in the schizophrenia group compared to the control
group because the D' values of the schizophrenia group
were higher than those of the controls [(SYN2-1 – SYN2-
2, 0.935 vs. 0.531 (schizophrenics vs. controls)), (SYN2-2
– SYN2-4, 0.750 vs. 0.453)] (Table 3). A similar situation
was also observed with the positive association of the
haplotype in CPLX2  with schizophrenia [CPLX2-1 –
CPLX2-2, 0.852 vs. 0.412 (schizophrenics vs. controls)]
(Table 5).
Chen et al. [23] recently reported an association study of
four SNPs in SYN2  using Han Chinese samples. They
found significant associations of SNP rs795009 and a
haplotype constructed by the four SNPs with schizophre-
nia. Chen et al. [23] and our study examined two SNPs
(rs2308169 and rs308963) in common, and their geno-
typic and allelic frequencies were similar in both studies.
Although Chen et al. [23] did not mention the pairwise
haplotype association study that we performed, they did
report a significant difference in the overall four-way hap-
lotype frequencies between schizophrenics and controls.
Since two independent studies have reported a significant
haplotype association of SYN2 with schizophrenia, this
gene is probably involved in the pathogenesis of
schizophrenia.
Several studies have suggested that the decreased expres-
sion of synaptic genes is characteristic of schizophrenia. In
the hippocampus of schizophrenic patients, several stud-
ies have shown a consistent pattern of decreases in presy-
naptic proteins and their encoding mRNAs, such as
synapsin 2, synaptophysin, and synaptosomal-associated
protein-25 (SNAP-25) [8-10,24]. Furthermore, a reduc-
tion in the synapsin 2 mRNA levels was observed in the
prefrontal cortex of schizophrenic patients [14], but
controvertible results have also been reported [25]. The
altered expression levels of other presynaptic proteins,
complexin 1 and complexin 2, have been reported in
schizophrenic patients [11-13]. Interestingly, complexin 1
is enriched in axosomatic regions, inhibitor neurons, and
their synapses, while complexin 2 is enriched in the axo-
dendritic terminals [9,26]. The differential expression of
complexins 1 and 2 implies their involvement in the exci-
tatory synapse in the hippocampus of schizophrenic
patients [11]. These observations suggest that abnormal
expression of SYN2 and CPLX2 may cause the vulnerabil-
ity to schizophrenia by altering neurotransmitter release
and neuroplasticity.
Conclusion
We found significant differences in the haplotype fre-
quencies in both SYN2  and  CPLX2  polymorphisms
between schizophrenia and control groups. In addition,
the haplotype constructed from three polymorphisms
(SYN2-1, SYN2-2, and SYN2-4) showed a significant asso-
ciation with schizophrenia. Our results suggest that both
SYN2 and CPLX2 polymorphisms may contribute suscep-
tibility to schizophrenia in the Korean population.
Methods
Subjects
A total of 154 unrelated Korean schizophrenia patients
(80 male and 74 female with a mean ± SD age of 43.8 ±
11.4 yr) and 133 unrelated Korean controls (64 male and
69 female; age 50.6 ± 11.7 yr) were recruited. For the
SYN2  analysis, 113 unrelated Korean schizophrenia
patients (60 male and 53 female with a mean ± SD age of
42.2 ± 11.3 yr) and 114 unrelated Korean controls (60
male and 54 female; age 51.7 ± 10.9 yr) were participated.
The schizophrenia patients were diagnosed using the
Diagnostic and Statistical Manual of Mental Disorders
(DSM)-IV criteria. The control subjects were recruited after
they had been designated as mentally healthy in a general
health check-up program. The average age of the controls
exceeded 50 years because we tried to avoid misincorpo-
ration of patients with late onset schizophrenia in the
control group, while it may produce statistical bias poten-
tially. Written informed consent was obtained from all
subjects. This study was approved by the Ethics Commit-
tee of Kyung Hee University, Faculty of Medicine.
Genomic DNA was extracted from whole blood cells
using a NucleoSpin® Blood kit (Macherey-Nagel, Easton,
PA).
SNP Selection and PCR-based Genotyping
Since the genomic sizes of SYN2 and CPLX2 are about 187
and 89 kb, respectively, we initially intended to select
common polymorphisms at intervals of approximately
20–50 kb from the dbSNP http://www.ncbi.nlm.nih.gov/
SNP/. After validating the frequency of each polymor-Behavioral and Brain Functions 2005, 1:15 http://www.behavioralandbrainfunctions.com/content/1/1/15
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phism in 24 healthy Korean individuals using direct
sequencing, we selected seven common polymorphisms
from SYN2 and five from CPLX2 for further analyses (Fig.
1, Table 1). We amplified the fragments containing poly-
morphisms individually and genotyped DNA samples for
each SNP with either PCR-based restriction fragment
length polymorphism (RFLP) assays or direct sequencing
performed with an ABI PRISM® Dye Terminator Cycle
Sequencing kit (Applied Biosystems, Foster City, CA) on
an ABI PRISM® 3100 DNA sequencer (Applied Biosys-
tems) (Table 1). In case of unclear sequence data, we
repeated direct sequencing under various conditions until
the genotype was determined correctly.
Statistics
The deviation of the genotypic frequencies from Hardy-
Weinberg equilibrium was examined using the chi-square
test (df = 1). Statistical differences in the genotypic distri-
butions and allelic frequencies between the schizophrenia
and control groups were examined using the Fisher's exact
probability test. We calculated D' and r2 to evaluate the
magnitude of linkage disequilibrium (LD) [19]. We esti-
mated haplotype frequencies using the EH program, ver-
sion 1.14 [20]. The statistical analysis of haplotype
association was done as previously described [21]. We
applied the Bonferroni correction to multiple testing
based on the number of haplotypes. The significance level
for all the statistical tests was 0.05.
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